Mitomycins

Generic Name: Mitomycins

Brand Names: Jelmyto, Mitosol, Mutamycin

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₁₈N_₄O_₅

CAS Number: 50-07-7

Unique Ingredient Identifier: 50SG953SK6

Background: Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of Streptomyces caespitosus. It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix. Few other antibiotics have been discov...

Indication: For treatment of malignant neoplasm of lip, oral cavity, pharynx, digestive organs, peritoneum, female breast, and urinary bladder. Also used as an adjunct to ab externo glaucoma surgery. Mitomycin is also indicated as a pyelocalyceal solution for the treatment of adults with low-grade upper tract urothelial cancer (LG-UTUC).

Associated Conditions: Anal Cancer, Bladder Cancer, Breast Cancer, Carcinoma of the Head and Neck, Cervical Cancer, Gastric Adenocarcinoma, Mesothelioma, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Adenocarcinoma, Ab externo surgery Glaucoma, Low-grade Upper Tract Urothelial Cancer (LG-UTUC)

Associated Therapies: -

Clinical Trials

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

Phase 2

Active, not recruiting

Conditions: Bladder Urothelial Carcinoma
Stage III Bladder Cancer AJCC v8

Interventions: Procedure: Biopsy of Bladder
Procedure: Biospecimen Collection
Drug: Cisplatin
Procedure: Computed Tomography
Procedure: Cystoscopy
Biological: Durvalumab
Other: Patient Observation
Drug: Gemcitabine Hydrochloride
Drug: Fluorouracil
Procedure: Magnetic Resonance Imaging
Drug: Mitomycin
Radiation: Radiation Therapy

First Posted Date: 2020-01-02

Last Posted Date: 2024-11-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 95

Registration Number: NCT04216290

Locations: 🇺🇸
Springfield Memorial Hospital, Springfield, Illinois, United States
🇺🇸
Logan Health Medical Center, Kalispell, Montana, United States
🇺🇸
Marshfield Medical Center - Minocqua, Minocqua, Wisconsin, United States

and more 214 locations

Chemoembolization for Lung Tumors

Phase 1

Completed

Conditions: Lung Metastases
Pleural Metastases
Mediastinal Metastases
Endobronchial Metastases

Interventions: Procedure: Chemoembolization
Drug: Mitomycin C
Drug: Lipiodol
Drug: Embospheres

First Posted Date: 2019-12-16

Last Posted Date: 2022-04-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 10

Registration Number: NCT04200417

Locations: 🇺🇸
Memoral Sloan Kettering Monmouth (Consent only), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Commack (Consent Only), Commack, New York, United States
🇺🇸
Memoral Sloan Kettering Westchester (Consent only), Harrison, New York, United States

and more 1 locations

Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study

Phase 2

Recruiting

Conditions: Stage I Anal Cancer AJCC v8
Stage IIA Anal Cancer AJCC v8
Anal Basaloid Carcinoma
Anal Canal Cloacogenic Carcinoma
Anal Canal Squamous Cell Carcinoma
Anal Margin Squamous Cell Carcinoma

Interventions: Drug: Capecitabine
Drug: Fluorouracil
Radiation: Intensity-Modulated Radiation Therapy
Drug: Mitomycin
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2019-11-18

Last Posted Date: 2024-08-07

Lead Sponsor: ECOG-ACRIN Cancer Research Group

Target Recruit Count: 252

Registration Number: NCT04166318

Locations: 🇺🇸
Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
🇺🇸
Providence Alaska Medical Center, Anchorage, Alaska, United States
🇺🇸
Fairbanks Memorial Hospital, Fairbanks, Alaska, United States

and more 649 locations

Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

Phase 2

Recruiting

Conditions: Gastric Cancer
Peritoneal Carcinomatosis

Interventions: Drug: Cisplatin
Drug: Mitomycin

First Posted Date: 2019-09-27

Last Posted Date: 2024-07-31

Lead Sponsor: University of Chicago

Target Recruit Count: 21

Registration Number: NCT04107077

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Efficacy of Topical Mitomycin C for Complex Benign Esophageal Anastomotic Strictures

Phase 2

Withdrawn

Conditions: Esophageal Stenosis
Anastomotic Stenosis

Interventions: Other: Control
Drug: Mitomycin C

First Posted Date: 2019-07-30

Last Posted Date: 2022-04-11

Lead Sponsor: Fox Chase Cancer Center

Registration Number: NCT04037072

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Decorin in Sub Scleral Trabeculectomy

Phase 1

Conditions: Primary Open-angle Glaucoma

Interventions: Drug: Decorin
Drug: Mitomycin c

First Posted Date: 2019-04-23

Last Posted Date: 2019-04-23

Lead Sponsor: Cairo University

Target Recruit Count: 52

Registration Number: NCT03924544

Locations: 🇪🇬
Cairo University, Cairo, Egypt

Prophylactic Surgery Plus HIPEC With CO2 in Patients Affected by Colorectal Carcinoma. CHECK Study.

Not Applicable

Recruiting

Conditions: Colorectal Neoplasms

Interventions: Procedure: HIPEC CO2 surgery
Procedure: Standard surgery
Drug: Mitomycin

First Posted Date: 2019-04-16

Last Posted Date: 2023-10-27

Lead Sponsor: Mario Negri Institute for Pharmacological Research

Target Recruit Count: 330

Registration Number: NCT03914820

Locations: 🇮🇹
Policlinico di Milano, Milano, Italy
🇮🇹
ASP PO Sant'Elia, Caltanissetta, Italy
🇮🇹
AOU Policlinico Paolo Giaccone, Palermo, Italy

and more 13 locations

Comparing Preoperative Injection of Mitomycin-C vs. Intraoperative Injection of Mitomycin-C vs. Topical Application of Mitomycin-C (Conventional Use) in Trabeculectomy

Phase 4

Terminated

Conditions: Glaucoma
Open Angle Glaucoma
Glaucoma Open-Angle Primary
Glaucoma, Open-Angle

Interventions: Drug: Mitomycin C

First Posted Date: 2019-03-15

Last Posted Date: 2024-01-05

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 19

Registration Number: NCT03875911

Locations: 🇺🇸
Doheny Eye Center UCLA (Pasadena), Pasadena, California, United States
🇺🇸
Doheny Eye Center UCLA (Arcadia), Arcadia, California, United States
🇺🇸
Stein Eye Institute - UCLA (Westwood), Los Angeles, California, United States

and more 1 locations

Sequential Combination Therapy in Bladder Cancer

Phase 4

Conditions: Bladder Cancer

Interventions: Drug: Mitomycin

First Posted Date: 2018-12-31

Last Posted Date: 2018-12-31

Lead Sponsor: Azienda Ospedaliera "Sant'Andrea"

Target Recruit Count: 140

Registration Number: NCT03790384

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

Phase 3

Active, not recruiting

Conditions: Muscle Invasive Bladder Carcinoma
Bladder Urothelial Carcinoma
Stage II Bladder Cancer AJCC v8
Stage IIIA Bladder Cancer AJCC v8

Interventions: Procedure: Biopsy of Bladder
Drug: Atezolizumab
Drug: Cisplatin
Procedure: Computed Tomography
Procedure: Cystoscopy
Drug: Gemcitabine
Drug: Fluorouracil
Procedure: Magnetic Resonance Imaging
Drug: Mitomycin
Other: Quality-of-Life Assessment
Radiation: Radiation Therapy
Other: Survey Administration
Procedure: Transurethral Resection of Bladder Tumor

First Posted Date: 2018-12-13

Last Posted Date: 2024-11-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 475

Registration Number: NCT03775265

Locations: 🇺🇸
Springfield Memorial Hospital, Springfield, Illinois, United States
🇺🇸
Henry Ford Saint John Hospital - Macomb Medical, Macomb, Michigan, United States
🇺🇸
Marshfield Medical Center - Minocqua, Minocqua, Wisconsin, United States

and more 366 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy